Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC Group aim to foster strategic and economic ties within India and China

July 12th 2011 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, announced today that its experts would be visiting China and India next month to boost partnerships and discuss future collaborations with leading regional pharmaceutical companies.

The visit to China comes on the back of ELC GROUP’s recent consultation work with one of the country’s largest pharmaceutical companies. ELC GROUP collaboration has seen the first successful entry into both European and American markets by a Chinese pharmaceutical company.

The industry itself is poised for significant growth in China due to the aging population and has recently become the world’s third-largest prescription drug market. ELC GROUP sees this as an interesting market opportunity for its other international clients to enter and is advising them accordingly.

During their Indian visit, ELC GROUP will be building on their strong regional presence. ELC GROUP currently supports a number of Indian drug companies providing scientific and regulatory advice, life-cycle management, pharmacovigilance and dossier development and marketing authorisations for the EU and USA. ELC GROUP will also be seeking to build new strategic and lucrative partnerships for its EU and US clients with Indian pharmaceutical producers.

ELC GROUP’s Akhil Jain said ‘Our target is to become the strategic resource for Indian customers. This will be executed by our trained regulatory Affairs team and tailor-made services. We are committed to necessary level of partnership with our customers to offer them services designed to fit their needs.’

ELC GROUP will soon be announcing a series of events for 2012 hosted by recent appointment to the ELC GROUP Board, Dr Paolo Biffignandi. These will be held in Mumbai, Hyderabad and Bangalore and will further enforce ELC GROUP as the industry experts in the region.